Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PODD
stocks logo

PODD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
767.52M
+28.46%
1.452
+26.24%
714.31M
+25.54%
1.195
+17.19%
769.82M
+18.6%
1.411
+20.62%
Estimates Revision
The market is revising Upward the revenue expectations for Insulet Corporation (PODD) for FY2025, with the revenue forecasts being adjusted by 2.63% over the past three months. During the same period, the stock price has changed by 8.79%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.63%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.28%
In Past 3 Month
Stock Price
Go Up
up Image
+8.79%
In Past 3 Month
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 368.43 USD with a low forecast of 300.00 USD and a high forecast of 415.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 368.43 USD with a low forecast of 300.00 USD and a high forecast of 415.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 336.840
sliders
Low
300.00
Averages
368.43
High
415.00
Current: 336.840
sliders
Low
300.00
Averages
368.43
High
415.00
Truist
Buy
maintain
$365 -> $390
2025-11-09
New
Reason
Truist
Price Target
$365 -> $390
2025-11-09
New
maintain
Buy
Reason
Truist raised the firm's price target on Insulet to $390 from $365 and keeps a Buy rating on the shares. The company posted another strong beat and raise on broad Omnipod 5 strength, the analyst tells investors in a research note. The firm remains confident in Insulet's prospects to sustain a well-above-average CAGR over the 2024-2028 period, Truist added.
Canaccord
Buy
maintain
$399 -> $428
2025-11-07
Reason
Canaccord
Price Target
$399 -> $428
2025-11-07
maintain
Buy
Reason
Canaccord raised the firm's price target on Insulet to $428 from $399 and keeps a Buy rating on the shares. The firm said Insulet delivered another strong beat-and-raise in Q3, driven by OUS outperformance and record new patient starts in US T1 and US T2.
Wells Fargo
NULL -> Overweight
maintain
$350 -> $360
2025-11-07
Reason
Wells Fargo
Price Target
$350 -> $360
2025-11-07
maintain
NULL -> Overweight
Reason
Wells Fargo raised the firm's price target on Insulet to $360 from $350 and keeps an Overweight rating on the shares. The firm notes the company posted a strong Q3 sales/EPS beat and raised FY25 guidance by more than 2-times the beat, mainly on U.S. growth.
UBS
Danielle Antalffy
Neutral
maintain
$320 -> $355
2025-11-07
Reason
UBS
Danielle Antalffy
Price Target
$320 -> $355
2025-11-07
maintain
Neutral
Reason
UBS analyst Danielle Antalffy raised the firm's price target on Insulet to $355 from $320 and keeps a Neutral rating on the shares. Broad-based strength and record new patients prompted an increase in Insulet's outlook, the analyst tells investors in a research note.
Barclays
NULL -> Overweight
maintain
$301 -> $316
2025-11-07
Reason
Barclays
Price Target
$301 -> $316
2025-11-07
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Insulet to $316 from $301 and keeps an Overweight rating on the shares. The firm views the company's Q3 report as "impressive."
Jefferies
Buy
maintain
$375 -> $400
2025-11-06
Reason
Jefferies
Price Target
$375 -> $400
2025-11-06
maintain
Buy
Reason
Jefferies raised the firm's price target on Insulet to $400 from $375 and keeps a Buy rating on the shares. The company reported a quarterly beat with health trends in T2, with total sales outperforming within and outside the U.S., the analyst tells investors in a research note. The firm is encouraged by the results, momentum in new customer starts, and the T2 pickup, and views Q4 guidance as conservative.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Insulet Corp (PODD.O) is 57.49, compared to its 5-year average forward P/E of 176.03. For a more detailed relative valuation and DCF analysis to assess Insulet Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
176.03
Current PE
57.49
Overvalued PE
290.22
Undervalued PE
61.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
64.71
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
93.38
Undervalued EV/EBITDA
36.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
13.88
Current PS
326.28
Overvalued PS
43.16
Undervalued PS
-15.41
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

PODD News & Events

Events Timeline

(ET)
2025-11-06
06:41:23
Insulet increases FY25 revenue growth forecast to 28%-29% from previous estimate of 24%-27%
select
2025-11-06
06:39:12
Insulet announces Q3 adjusted EPS of $1.24, surpassing consensus estimate of $1.15
select
2025-09-16 (ET)
2025-09-16
07:10:48
Insulet anticipates Q3 revenue growth surpassing 22%-25% expectations.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
11-12NASDAQ.COM
Zacks.com Spotlights Insulet, Celestica, and Innodata

  • Government Shutdown Update: The Senate has approved a bipartisan bill to end the 41-day government shutdown, the longest in U.S. history, with President Trump supporting the reopening, which has positively impacted Wall Street and momentum stocks.

  • Momentum Stock Strategy: Investors are encouraged to use the Driehaus strategy, which focuses on buying stocks that are increasing in price, with a strong emphasis on earnings growth and positive relative strength indicators.

  • Highlighted Stocks: Three momentum stocks selected using the Driehaus strategy are Insulet Corp. (PODD), Celestica Inc. (CLS), and Innodata Inc. (INOD), all of which have received high momentum scores and demonstrated significant earnings surprises.

  • Investment Resources: Zacks Investment Research offers tools like the Research Wizard for investors to create and test their own stock-picking strategies, emphasizing the importance of informed investment decisions.

[object Object]
Preview
6.5
11-12NASDAQ.COM
3 Leading Momentum Stocks to Consider as U.S. Shutdown Approaches Conclusion

  • Government Shutdown Update: The Senate has passed a bipartisan bill to end the longest government shutdown in U.S. history, with President Trump supporting the reopening, although final approval may be delayed due to the House being on recess.

  • Investment Strategy: Investors are encouraged to use the Driehaus strategy, which focuses on buying stocks that are increasing in price, and to consider momentum stocks like Insulet Corporation, Celestica Inc., and Innodata Inc. as potential picks.

  • Key Investment Criteria: The strategy emphasizes strong earnings growth, positive earnings surprises, and a favorable momentum score, narrowing down the stock selection to 13 candidates based on specific performance metrics.

  • Research Tools: Zacks Investment Research offers tools like the Research Wizard for investors to create and test their own strategies, highlighting the importance of using data-driven approaches for better investment outcomes.

[object Object]
Preview
4.0
11-11NASDAQ.COM
Insulet (PODD) Receives Strong Buy Upgrade: Key Information to Consider

  • Insulet's Upgrade: Insulet Corporation (PODD) has been upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in earnings estimates, indicating a positive outlook for its stock price.

  • Earnings Estimates Impact: The Zacks rating system, which correlates earnings estimate revisions with stock price movements, suggests that rising earnings estimates for Insulet could lead to higher stock valuations and favorable investor sentiment.

  • Zacks Rank System: The Zacks Rank system classifies stocks based on earnings estimates, with only the top 5% receiving a "Strong Buy" rating, highlighting Insulet's strong position among its peers.

  • Future Earnings Projections: For the fiscal year ending December 2025, Insulet is expected to earn $4.83 per share, with analysts raising their estimates by 5.2% over the past three months, reflecting confidence in the company's growth potential.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Insulet Corp (PODD) stock price today?

The current price of PODD is 336.84 USD — it has increased 3.24 % in the last trading day.

arrow icon

What is Insulet Corp (PODD)'s business?

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

arrow icon

What is the price predicton of PODD Stock?

Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 368.43 USD with a low forecast of 300.00 USD and a high forecast of 415.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Insulet Corp (PODD)'s revenue for the last quarter?

Insulet Corp revenue for the last quarter amounts to 706.30M USD, increased 29.86 % YoY.

arrow icon

What is Insulet Corp (PODD)'s earnings per share (EPS) for the last quarter?

Insulet Corp. EPS for the last quarter amounts to 1.24 USD, increased 14.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Insulet Corp (PODD)'s fundamentals?

The market is revising Upward the revenue expectations for Insulet Corporation (PODD) for FY2025, with the revenue forecasts being adjusted by 2.63% over the past three months. During the same period, the stock price has changed by 8.79%.
arrow icon

How many employees does Insulet Corp (PODD). have?

Insulet Corp (PODD) has 3900 emplpoyees as of November 13 2025.

arrow icon

What is Insulet Corp (PODD) market cap?

Today PODD has the market capitalization of 23.70B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free